Net clinical benefit of extended dual pathway inhibition in chronic coronary syndrome as classified by the 2024 ESC criteria: a COMPASS substudy
In CCS patients, DPI reduced all-cause death and MACE while increasing major bleeding. The 2024 ESC criteria performed poorly in terms of distinguishing patients at high vs. low ischemic risk, making them inadequate to provide guidance for DPI use.
Authors
- Kevin Kris Warnakula Olesen (ORCID: https://orcid.org/0000-0002-0560-3615)
- Morten Würtz (ORCID: https://orcid.org/0000-0001-7150-7704)
- Qilong Yi
- Michael Maeng
- John W Eikelboom
Institutions
- University of Ottawa (CA)
- Aarhus University (DK)
- Aarhus University Hospital (DK)
- Population Health Research Institute (CA)
- Regionshospitalet Herning (DK)
- Ottawa Public Health (CA)
Publication Details
- Journal
- European Heart Journal - Cardiovascular Pharmacotherapy
- Published
- 2026-01-29
- DOI
- https://doi.org/10.1093/ehjcvp/pvag008
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00